GSK, Vir Biotech to expand COVID-19 research partnership for other diseases
As a part of the deal to research and develop monoclonal antibody treatments for influenza and other respiratory illnesses, GSK will make a further $120 million equity investment in Vir and an additional upfront payment of $225 million.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | COVID-19 | Influenza | Partnerships | Pharmaceuticals | Respiratory Medicine